Ocular Therapeutix’s Wet AMD Candidate Shows Sustained, Comparable Clinical Activity Vs. Eylea
Ocular Therapeutix Inc (NASDAQ:OCUL) announced interim 7-month data from its U.S. Phase 1 trial evaluating OTX-TKI for wet age-related macular degeneration…